First Seven-Day Treatment of H. Pylori Infection Approved by FDA - Aciphex(R) (rabeprazole sodium) Plus Antibiotics

Faster Than Currently Approved Options -



    TEANECK, N.J., and TITUSVILLE, N.J., Nov. 14 /PRNewswire/ -- Aciphex, a
 proton pump inhibitor (PPI) widely prescribed for gastroesophageal reflux
 disease (GERD), is now approved by the Food and Drug Administration as part of
 the first seven-day treatment for Helicobacter pylori (H. pylori) infection,
 the single most common cause of peptic ulcers.  Taken in combination with
 certain antibiotics, Aciphex offers a faster therapy option than other PPIs,
 treating H. pylori in up to half the time of current 10 to 14 day treatments.
     When used in combination with amoxicillin and clarithromycin as a
 three-drug regimen, Aciphex is indicated for the treatment of patients with H.
 pylori infection and duodenal ulcer disease (active or history within the last
 five years) to eradicate H. pylori.
     Up to 60 million American adults are currently infected with H. pylori (a
 type of bacteria in the stomach); as many as one in 10 Americans will develop
 an ulcer in their lifetime.
     "Using Aciphex, plus antibiotics for one week to eradicate H. pylori is a
 faster treatment option than what is currently available," said Nimish Vakil,
 M.D., Clinical Professor of Medicine at the University of Wisconsin Medical
 School (Milwaukee, Wis.).  "When you consider the fact that the majority of
 duodenal and gastric ulcers are caused by H. pylori infection and that a short
 treatment course eradicates the infection and prevents relapse, you can
 understand the importance of this infection in ulcer disease."
     A multicenter, double-blind, placebo-controlled trial was conducted in
 803 patients infected with H. pylori at 47 centers nationwide.  In the study,
 84 percent of patients treated with Aciphex(R) (rabeprazole sodium),
 amoxicillin and clarithromycin taken twice daily were free of H. pylori after
 seven days of therapy.  Eighty-six percent of patients taking the identical
 regimen achieved the same result after 10 days of treatment, with no
 significant difference obtained with three additional days of therapy.  H.
 pylori was eradicated in 82 percent of patients treated with a combination of
 omeprazole, amoxicillin and clarithromycin taken twice daily for 10 days based
 on per protocol analysis.  The three-day Aciphex, amoxicillin and
 clarithromycin treatment arm was clinically sub-optimal for H. pylori
 eradication.  Eradication of bacteria was determined by a negative Urea Breath
 Test (13C-UBT) at 42 or more days after the end of therapy.
     In clinical trials using combination therapy with rabeprazole plus
 amoxicillin and clarithromycin (RAC), no adverse events unique to this drug
 combination were observed.  In the U.S. multicenter study, the most frequently
 reported drug related adverse events for patients who received RAC therapy for
 seven or 10 days were diarrhea (8 percent and 7 percent) and taste perversion
 (6 percent and 10 percent) respectively.
     No clinically significant laboratory abnormalities particular to the drug
 combinations were observed.
     For more information on adverse events or laboratory changes with
 amoxicillin or clarithromycin, refer to their respective package prescribing
 information.
     Clarithromycin is contraindicated in patients taking cisapride or
 pimozide; or in patients with a known hypersensitivity to clarithromycin or
 any macrolide antibiotic.  Clarithromycin may elevate digoxin serum
 concentrations.  Serum digoxin levels should be carefully monitored while
 digoxin and clarithromycin are taken concomitantly.  Clarithromycin should not
 be used in pregnant women except in circumstances where no alternative therapy
 is appropriate.  Amoxicillin is contraindicated in patients who are allergic
 to any penicillin.
 
     About Aciphex(R)(rabeprazole sodium)
     Aciphex is also indicated for the treatment of symptomatic GERD, healing
 of erosive GERD, maintenance of healed erosive GERD, healing of duodenal
 ulcers and treatment of symptoms related to these conditions.  In addition,
 Aciphex is approved for the treatment of pathological hypersecretory
 conditions, including Zollinger-Ellison syndrome, a rare disorder that causes
 the stomach to produce excess acid.
     Aciphex has a well-established safety record.  In studies, the most common
 side effect possibly related to Aciphex was headache (2.4 percent vs
 1.6 percent for sugar pill).  Aciphex should not be used if you have had an
 allergic reaction to Aciphex, its tablet ingredients, or any proton pump
 inhibitor (PPI).  Reduction in symptoms during treatment with Aciphex does not
 rule out the presence of gastric malignancy.  Patients treated with a PPI,
 like Aciphex, and warfarin (such as Coumadin(R)(1)) may need to be monitored
 more closely by their doctor.
     Aciphex is a registered trademark of Eisai Co., Ltd., Tokyo, Japan, and is
 co-promoted by Eisai Inc. and Janssen Pharmaceutica, Inc. in the United
 States.
 
     About Eisai Inc.
     Eisai Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd., a
 research-based human health care company that discovers, develops and markets
 products in more than 30 countries.  Established in 1995, Eisai Inc. began
 marketing its first product in the United States in 1997 and has rapidly grown
 to become an integrated pharmaceutical business with sales of more than
 $1 billion in fiscal year 2001 (year ending March 31, 2002).  Eisai Inc.
 employs a total of more than 600 people at its headquarters in Teaneck, N.J.,
 at its state-of-the-art pharmaceutical production and formulation research and
 development facility in Research Triangle Park, N.C., and in the field.
 Between 1998 and 2001, Eisai Inc. moved up rapidly in the rankings of U.S.
 pharmaceutical companies (based on revenues) from No. 44 to 23.
 
     About Janssen Pharmaceutica, Inc.
     Janssen Pharmaceutica, Inc. markets therapies for gastrointestinal
 disorders, psychiatric and neurological conditions, chronic pain, and fungal
 infections.  Janssen Pharmaceutica, Inc.'s international operations are
 headquartered in Beerse, Belgium, with affiliates in 32 countries; Janssen's
 U.S. headquarters are based in Titusville, NJ.  Janssen Pharmaceutica, Inc. is
 a wholly owned subsidiary of Johnson & Johnson, the world's most comprehensive
 manufacturer of health care products and related services.
 
     For more information about Aciphex(R)(rabeprazole sodium) visit
 http://www.aciphex.com or call Eisai Inc. at 1-888-4ACIPHEX or Janssen
 Pharmaceutica, Inc. at 1-800-JANSSEN.  Please see package insert or link below
 for full prescribing information:
 
     (1) Coumadin is a registered trademark of Bristol-Myers Squibb Pharma
         Company.
 
     (Photo: http://www.newscom.com/cgi-bin/prnh/20021114/NYTH037-a
             http://www.newscom.com/cgi-bin/prnh/20021114/NYTH037-b )
 
                      Make Your Opinion Count - Click Here
                http://tbutton.prnewswire.com/prn/11690X65274681
 
 

SOURCE Eisai Inc.; Janssen Pharmaceutica, Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.